Home | Blood, Heart and Circulation

Blood, Heart and Circulation

Largest population-based study confirms patients taking some cholesterol-lowering drugs have increased risk of developing diabetes

By Leslie Shepherd - The largest study to date has confirmed that elderly patients who take certain high-potency cholesterol-lowering drugs known as ...

Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles

The new agreement was negotiated through Blue Mountain Technologies, a program of Mount Sinai Innovation Partners. ...

Heart failure accelerates male ‘menopause’

Four-fold increase of andropausal syndrome in men with heart failure ... Full story

First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half in randomised double blind trial ... Full story

Youth with Type 2 diabetes at much higher risk for heart, kidney disease

SAN ANTONIO — The news about youth and diabetes keeps getting worse. The latest data from the national TODAY diabetes study shows that children who develop Type 2 diabetes are at high risk to develop heart, kidney and eye problems faster and at a higher rate than people who acquire Type 2 diabetes as adults. ... Full story

Death rates decline for advanced heart failure patients, but outcomes are still not ideal

UCLA study looks in detail at thousands of patients treated over last 20 years ... Full story

STUDY LINKS CHEMICALS WIDELY FOUND IN PLASTICS AND PROCESSED FOOD TO ELEVATED BLOOD PRESSURE IN CHILDREN AND TEENS

Data from nearly 3,000 children shows dietary exposure to certain plastics may play a hidden role in epidemic increases in childhood hypertension ... Full story

Post-approval TAVI registry shows high rates of device success at one year

One-year results from SOURCE XT – one of the largest, post-approval transcatheter aortic valve implantation (TAVI) registries ... Full story

Biodegradable Orsiro stent proves non-inferior to Xience Prime drug-eluting stent for in-stent late lumen loss at nine months

Paris, France: The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today. ... Full story

first back 11 12 13 14 15 16 17 18 19 20 next last total: 2271 | displaying: 181 - 190